NIH R01 · 2025
Immune signatures of CMV disease risk after orthotopic liver transplant
ABSTRACT: Background: Cytomegalovirus (CMV) is a highly seroprevalent human herpesvirus (HHV) of particular clinical significance in the immunocompromised patient population. Solid organ transplant (SOT) from a CMV-infected donor (D+) to a naïve recipient (D+/R-) leads to a unique mechanism of primary CMV infection in ~80% of recipients. CMV disease, such as pneumonitis, retinitis, or primary CMV syndrome, occurs in ~30% of patients, most commonly after cessation of antiviral prophylaxis after day 100. The immune mechanisms of protection from disease risk in this scenario are not known, but this risk was reduced to 10% in a randomized, controlled trial of pre-emptive therapy vs prophylaxis…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.